Artis BioSolutions (“Artis”), a San Diego-based advanced-therapies development and manufacturing company, announces that it has entered into a definitive agreement to acquire Syngoi Technologies (“Syngoi”), a Spanish biotechnology company pioneering novel enzymatic approaches for manufacturing synthetic DNA technologies. The acquisition will advance Artis’ strategy of building a differentiated platform to accelerate gene-to-drug discovery across a range of therapeutic modalities by adding fast and cost-effective enzymatic-based synthetic DNA manufacturing capabilities.
Read the full article: Artis BioSolutions Announces Agreement to Acquire Syngoi Technologies to Deliver Next Generation Solutions for Synthetic DNA Technology //
Source: https://www.businesswire.com/news/home/20260106436676/en/Artis-BioSolutions-Announces-Agreement-to-Acquire-Syngoi-Technologies-to-Deliver-Next-Generation-Solutions-for-Synthetic-DNA-Technology